Genelabs/Watson Aslera Lupus Deal Includes $30.5 Mil. In Up-Front Payments

20 Nov 2000

• By The Pink Sheet

Watson Pharmaceuticals is investing $30.5 mil. up front to help Genelabs Technologies bring its systemic lupus erythematosus treatment Aslera (prasterone) to market, the companies jointly announced Nov. 13.

Genelabs/Watson Aslera Lupus Deal Includes $30.5 Mil. In Up-Front Payments

More from Archive

More from Pink Sheet